Product Description: Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC50s of 79 nM and 497 nM for F508del and G551D CFTR, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research[1].
Applications: COVID-19-immunoregulation
Formula: C12H13F6N3O3
References: [1]Darren Le Grand, et al. Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. J Med Chem. 2021 Jun 10;64(11):7241-7260./[2]Steven M Rowe, et al. Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial. Int J Chron Obstruct Pulmon Dis. 2020 Oct 5;15:2399-2409.
CAS Number: 1334546-77-8
Molecular Weight: 361.24
Compound Purity: 99.87
Research Area: Inflammation/Immunology
Solubility: DMSO : 150 mg/mL (ultrasonic;warming;heat to 60°C)
Target: CFTR
English
Deutsch
